60 Degrees Pharmaceuticals, Inc. (SXTPW) — 8-K Filings

8-K Filings (26)

• 60 Degrees Pharmaceuticals Files 8-K on Shareholder Vote Matters — Oct 10, 2025 Risk: low
  On October 8, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing was made pu
• 60 Degrees Pharmaceuticals Files 8-K — Sep 9, 2025 Risk: low
  On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regula
• 60 Degrees Pharmaceuticals Enters and Terminates Agreements — Sep 5, 2025 Risk: medium
  On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The com
• 60 Degrees Pharmaceuticals Files 8-K — Jul 18, 2025 Risk: medium
  On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware, filed an 8-K report deta
• 60 Degrees Pharmaceuticals Files 8-K for Other Event — Apr 9, 2025 Risk: medium
  On April 4, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing an "Other Event." The filing does not specify the nature of this event but indi
• 60 Degrees Pharmaceuticals Files 8-K — Feb 6, 2025 Risk: medium
  On February 5, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity se
• 60 Degrees Pharmaceuticals Files 8-K — Jan 30, 2025 Risk: medium
  On January 28, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity se
• 60 Degrees Pharmaceuticals Files 8-K — Jan 28, 2025 Risk: low
  On January 28, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no
• 60 Degrees Pharmaceuticals Files 8-K — Jan 8, 2025 Risk: low
  On January 8, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no
• 60 Degrees Pharmaceuticals Files 8-K on Shareholder Vote Matters — Nov 6, 2024 Risk: low
  On November 6, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorpor
• 60 Degrees Pharmaceuticals Files 8-K — Oct 8, 2024 Risk: low
  On October 2, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware,
• 60 Degrees Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Sep 6, 2024 Risk: medium
  On September 4, 2024, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity s
• 60 Degrees Pharmaceuticals Files 8-K — Aug 28, 2024 Risk: low
  On August 26, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware
• 60 Degrees Pharmaceuticals Files 8-K — Aug 14, 2024 Risk: low
  On August 12, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not d
• 60 Degrees Pharmaceuticals Files 8-K — Aug 12, 2024 Risk: low
  On August 12, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws, a
• 60 Degrees Pharmaceuticals Files 8-K — Jul 26, 2024 Risk: low
  On July 25, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicatin
• 60 Degrees Pharmaceuticals Files 8-K Report — Jul 16, 2024 Risk: low
  On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is a Delaware-incorporated entity with its princip
• 60 Degrees Pharmaceuticals Files 8-K — Jul 9, 2024 Risk: low
  On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," ind
• 60 Degrees Pharmaceuticals Files 8-K — Jun 27, 2024 Risk: low
  On June 27, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific materi
• 60 Degrees Pharmaceuticals Files 8-K — Jun 12, 2024 Risk: low
  On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," in
• 60 Degrees Pharmaceuticals Files 8-K — May 2, 2024 Risk: low
  On April 26, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
• 60 Degrees Pharmaceuticals Files 8-K — Mar 15, 2024 Risk: low
  On March 15, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine u
• 60 Degrees Pharma Delisted from Nasdaq, Moves to OTC Pink — Feb 28, 2024 Risk: high
  60 DEGREES PHARMACEUTICALS, INC. (SXTP) received a delisting notice from Nasdaq on February 27, 2024, due to its common stock failing to maintain a minimum bid
• 60 Degrees Pharma Enters Material Definitive Agreement — Feb 20, 2024 Risk: low
  60 Degrees Pharmaceuticals, Inc. entered into a Material Definitive Agreement on February 13, 2024. The filing indicates the company's common stock has a par va
• 60 DEGREES PHARMACEUTICALS Enters Material Definitive Agreement — Feb 2, 2024
  60 DEGREES PHARMACEUTICALS, INC. filed an 8-K on February 2, 2024, reporting an event on January 29, 2024, related to an "Entry into a Material Definitive Agree
• 60 Degrees Pharma Files 8-K on Common Stock & Warrants — Jan 16, 2024
  60 DEGREES PHARMACEUTICALS, INC. filed an 8-K on January 16, 2024, reporting an event on January 10, 2024, related to its Common Stock, par value $0.0001 per sh

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX